Industry Observations on Immune Checkpoint-Related Antibody Reagents and Companion Diagnostic Development

Research on immune checkpoints and demand for tool reagents

Research related to immune checkpoints involves recombinant proteins, monoclonal antibodies, polyclonal antibodies, flow cytometry antibodies, immunohistochemistry antibodies, ELISA kits, cell function assay reagents, etc. In target validation, antibody screening, functional evaluation, and biomarker analysis, R&D institutions and biopharmaceutical companies have high requirements for reagent specificity, batch-to-batch consistency, and activity stability. Common specifications such as lyophilized powder or liquid storage forms, flow cytometry antibodies with different labels (such as FITC, PE, APC), and immunohistochemistry antibodies validated for paraffin sections all require clear application instructions and quality data.

During the screening stage, researchers usually focus on the purity, endotoxin level, and whether the native conformation is maintained of recombinant proteins. In general requirements, recombinant protein purity is commonly above 95%, and endotoxin content can be detected by the Limulus amebocyte lysate method and expressed in EU/mg, but specific values vary by product, and absolute statements should be avoided. These parameters need to be provided by manufacturers in the form of batch inspection reports or certificates of analysis.

Quality control focus points for antibodies and recombinant proteins

The stability of upstream biological reagents directly affects downstream experimental results. Manufacturers should establish quality control strategies from aspects such as raw material sources, clone selection, purification processes, buffer systems, and storage conditions. Common control items include:

Specificity verification: confirm binding to the target immune checkpoint protein by immunoblotting, flow cytometry, immunohistochemistry, or enzyme-linked immunosorbent assay;

Activity evaluation: perform functional verification using cell binding assays or ligand-receptor blocking assays;

Batch-to-batch consistency: reduce batch differences by defining key process parameters and comparing with reference materials;

Stability studies: examine activity retention under different temperatures, repeated freeze-thaw cycles, and light exposure.

It should be noted that these verifications belong to the general quality requirements for research-use reagents. For reagents used in clinical diagnosis or companion diagnostics, analytical performance evaluation and clinical evaluation should also be carried out in accordance with relevant regulations for in vitro diagnostic reagent registration, and research data alone cannot be used as a substitute.

Compliance pathway for companion diagnostic reagent development

Companion diagnostics are detection methods used to determine whether a patient is suitable for receiving a specific drug treatment. Taking companion diagnostics related to immune checkpoint inhibitors as an example, common detection markers include PD-L1 expression level, mismatch repair function, etc. Developing such reagents requires attention to marker selection, antibody clone performance, cutoff threshold setting, sample type, and pre-treatment conditions. Different drugs may correspond to different companion diagnostic systems and interpretation standards, and companies should refer to relevant guidelines issued by regulatory authorities.

For in vitro diagnostic reagents to be marketed domestically, it is generally necessary to complete product technical requirement formulation, analytical performance evaluation, stability studies, clinical evaluation, and production quality management system audits. For immunohistochemistry reagents, antigen retrieval methods, antibody incubation conditions, control settings, and interpretation methods also need to be clarified. During the registration process, the detection system needs to remain consistent with the detection method used in drug clinical trials or undergo bridging studies.

Supply chain and localization opportunities

The market for immune checkpoint-related antibodies, recombinant proteins, and detection kits was previously dominated by multinational brands. In recent years, domestic biological reagent and medical device companies have continued to invest in this field and have gradually provided more localized options. For downstream users, supply chain stability, technical support response speed, customized services, and completeness of compliance documents have become important considerations in selecting suppliers.

Driven by policies such as the medical device marketing authorization holder system, some companies have begun to integrate antibody raw materials, kit development, and registration services, forming a chain from research tools to clinical companion diagnostics. At the same time, capabilities such as cold chain transportation, batch traceability, and electronic quality documentation also affect companies' recognition among hospitals and third-party testing institutions.

Overall, immune checkpoint-related reagents and companion diagnostics are still in a stage of rapid evolution. Only by continuously building capabilities in raw material quality control, methodological validation, registration compliance, and supply chain management can companies better meet the diverse needs of tumor immunology research and clinical testing.